Oxford University researchers have worked in collaboration with industry leaders NuCana to assess a novel chemotherapy drug derived from a fungus. Further Phase 2 clinical trials of this drug are now being planned in partnership with NuCana, to add to growing number of ProTide technology cancer drugs that are being developed to treat cancer. ProTide technology was invented by NuCana's late Chief Scientific Officer, Professor Christopher McGuigan at Cardiff University. The clinical trial was led from the Oxford Early Phase Clinical Trials Unit, with additional recruitment in Edinburgh and Newcastle. Utilising their proprietary technology, NuCana are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
